XORTX Therapeutics (XRTX) Restructuring Costs (2022 - 2026)

XORTX Therapeutics' (XRTX) quarterly Restructuring Costs came in at $47474.0 in Q1 2026, up 110.14% on a QoQ basis from $22592.0 in Q3 2025.

XORTX Therapeutics (XRTX) Restructuring Costs (2022 - 2026) Analysis & Trends

XORTX Therapeutics (XRTX) has 5 years of Restructuring Costs data on file, last reported at $47474.0 in Q1 2026.

Quarterly Restructuring Costs changed N/A year-over-year to $47474.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19411.4 (changed N/A YoY) and the FY2025 annual result came in at $86126.3, down 16.61% from the prior year.
Restructuring Costs rose to $47474.0 in Q1 2026, from $22592.0 in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of $47474.0 in Q1 2026 to a low of -$81477.6 in Q4 2023.
A 5-year average of $18464.8 and a median of $30823.0 in 2024 frame the typical range for Restructuring Costs.
The widest YoY moves for Restructuring Costs: up 77.57% in 2023, down 453.57% in 2023.
Tracing XRTX's Restructuring Costs over 5 years: stood at $23044.1 in 2022, then tumbled by 453.57% to -$81477.6 in 2023, then soared by 137.83% to $30823.0 in 2024, then dropped by 26.7% to $22592.0 in 2025, then jumped by 110.14% to $47474.0 in 2026.
The last three Restructuring Costs figures came in at $47474.0 (Q1 2026), $22592.0 (Q3 2025), and $30823.0 (Q3 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	XORTX Therapeutics	2.78 Mn	2.78 Mn	-

Download Data